References
1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG,
Enriquez-Sarano M. Burden of valvular heart diseases: a population-based
study. Lancet 2006;368:1005-11.
2. Andell P, Li X, Martinsson A et al. Epidemiology of valvular heart
disease in a Swedish nationwide hospital-based register study. Heart
2017;103:1696-1703.
3. Levine RA, Hagege AA, Judge DP et al. Mitral valve
disease–morphology and mechanisms. Nat Rev Cardiol 2015;12:689-710.
4. Zoghbi WA, Adams D, Bonow RO et al. Recommendations for Noninvasive
Evaluation of Native Valvular Regurgitation: A Report from the American
Society of Echocardiography Developed in Collaboration with the Society
for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr
2017;30:303-371.
5. El Sabbagh A, Reddy YNV, Nishimura RA. Mitral Valve Regurgitation in
the Contemporary Era: Insights Into Diagnosis, Management, and Future
Directions. JACC Cardiovasc Imaging 2018;11:628-643.
6. Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for
the management of valvular heart disease. Eur Heart J 2017;38:2739-2791.
7. Garg P, Swift AJ, Zhong L et al. Assessment of mitral valve
regurgitation by cardiovascular magnetic resonance imaging. Nat Rev
Cardiol 2020;17:298-312.
8. Blanken CPS, Farag ES, Boekholdt SM et al. Advanced cardiac MRI
techniques for evaluation of left-sided valvular heart disease. J Magn
Reson Imaging 2018;48:318-329.
9. Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA/ACC Focused Update of
the 2014 AHA/ACC Guideline for the Management of Patients With Valvular
Heart Disease: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines.
Circulation 2017;135:e1159-e1195.
10. Uretsky S, Argulian E, Narula J, Wolff SD. Use of Cardiac Magnetic
Resonance Imaging in Assessing Mitral Regurgitation: Current Evidence. J
Am Coll Cardiol 2018;71:547-563.
11. Thomas N, Unsworth B, Ferenczi EA, Davies JE, Mayet J, Francis DP.
Intraobserver variability in grading severity of repeated identical
cases of mitral regurgitation. Am Heart J 2008;156:1089-94.
12. Biner S, Rafique A, Rafii F et al. Reproducibility of proximal
isovelocity surface area, vena contracta, and regurgitant jet area for
assessment of mitral regurgitation severity. JACC Cardiovasc Imaging
2010;3:235-43.
13. Grayburn PA, Bhella P. Grading severity of mitral regurgitation by
echocardiography: science or art? JACC Cardiovasc Imaging 2010;3:244-6.
14. Uretsky S, Gillam L, Lang R et al. Discordance between
echocardiography and MRI in the assessment of mitral regurgitation
severity: a prospective multicenter trial. J Am Coll Cardiol
2015;65:1078-88.
15. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ.
Interstudy reproducibility of right ventricular volumes, function, and
mass with cardiovascular magnetic resonance. Am Heart J 2004;147:218-23.
16. Bellenger NG, Burgess MI, Ray SG et al. Comparison of left
ventricular ejection fraction and volumes in heart failure by
echocardiography, radionuclide ventriculography and cardiovascular
magnetic resonance; are they interchangeable? Eur Heart J
2000;21:1387-96.
17. Grothues F, Smith GC, Moon JC et al. Comparison of interstudy
reproducibility of cardiovascular magnetic resonance with
two-dimensional echocardiography in normal subjects and in patients with
heart failure or left ventricular hypertrophy. Am J Cardiol
2002;90:29-34.
18. Buchner S, Poschenrieder F, Hamer OW et al. Direct visualization of
regurgitant orifice by CMR reveals differential asymmetry according to
etiology of mitral regurgitation. JACC Cardiovasc Imaging
2011;4:1088-96.
19. Gabriel RS, Kerr AJ, Raffel OC, Stewart RA, Cowan BR, Occleshaw CJ.
Mapping of mitral regurgitant defects by cardiovascular magnetic
resonance in moderate or severe mitral regurgitation secondary to mitral
valve prolapse. J Cardiovasc Magn Reson 2008;10:16.
20. Han Y, Peters DC, Salton CJ et al. Cardiovascular magnetic resonance
characterization of mitral valve prolapse. JACC Cardiovasc Imaging
2008;1:294-303.
21. Myerson SG, d’Arcy J, Christiansen JP et al. Determination of
Clinical Outcome in Mitral Regurgitation With Cardiovascular Magnetic
Resonance Quantification. Circulation 2016;133:2287-96.
22. Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G.
Prognostic Implications of Magnetic Resonance-Derived Quantification in
Asymptomatic Patients With Organic Mitral Regurgitation: Comparison With
Doppler Echocardiography-Derived Integrative Approach. Circulation
2018;137:1349-1360.
23. Chinitz JS, Chen D, Goyal P et al. Mitral apparatus assessment by
delayed enhancement CMR: relative impact of infarct distribution on
mitral regurgitation. JACC Cardiovasc Imaging 2013;6:220-34.
24. Srichai MB, Grimm RA, Stillman AE et al. Ischemic mitral
regurgitation: impact of the left ventricle and mitral valve in patients
with left ventricular systolic dysfunction. Ann Thorac Surg
2005;80:170-8.
25. Bogabathina H, Doyle M, Williams R, Yamrozik J, Vido D, Biederman
RW. Is there an alternative explanation to post-myocardial infarction
emergence of mitral regurgitation? A CMR-LGE observational study. J
Heart Valve Dis 2013;22:669-74.
26. Cavalcante JL, Kusunose K, Obuchowski NA et al. Prognostic Impact of
Ischemic Mitral Regurgitation Severity and Myocardial Infarct
Quantification by Cardiovascular Magnetic Resonance. JACC Cardiovasc
Imaging 2019.
27. Kwon DH, Kusunose K, Obuchowski NA et al. Predictors and Prognostic
Impact of Progressive Ischemic Mitral Regurgitation in Patients With
Advanced Ischemic Cardiomyopathy: A Multimodality Study. Circ Cardiovasc
Imaging 2016;9.
28. Nishimura RA, Otto CM, Bonow RO et al. 2014 AHA/ACC Guideline for
the Management of Patients With Valvular Heart Disease: a report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines. Circulation 2014;129:e521-643.
29. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ,
Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR)
protocols: 2020 update. J Cardiovasc Magn Reson 2020;22:17.
30. Cain PA, Ahl R, Hedstrom E et al. Age and gender specific normal
values of left ventricular mass, volume and function for gradient echo
magnetic resonance imaging: a cross sectional study. BMC Med Imaging
2009;9:2.
31. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER et al. Normal
values for cardiovascular magnetic resonance in adults and children. J
Cardiovasc Magn Reson 2015;17:29.
32. Thavendiranathan P, Phelan D, Thomas JD, Flamm SD, Marwick TH.
Quantitative assessment of mitral regurgitation: validation of new
methods. J Am Coll Cardiol 2012;60:1470-83.
33. Krombach GA, Kuhl H, Bucker A et al. Cine MR imaging of heart valve
dysfunction with segmented true fast imaging with steady state free
precession. J Magn Reson Imaging 2004;19:59-67.
34. Uretsky S, Chaudhry FA, Gillam L et al. A novel technique to
quantify the instantaneous mitral regurgitant rate. J Cardiovasc Magn
Reson 2013;15:74.
35. Uretsky S, Aldaia L, Marcoff L et al. The Effect of Systolic
Variation of Mitral Regurgitation on Discordance Between Noninvasive
Imaging Modalities. JACC Cardiovasc Imaging 2019;12:2431-2442.
36. Khan MS, Biederman R. Dynamic cardiac anatomy: the ”cypress tree”
papillary muscle root. J Cardiovasc Thorac Res 2018;10:138-143.
37. Reddy ST, Shah M, Doyle M et al. Evaluation of cardiac valvular
regurgitant lesions by cardiac MRI sequences: comparison of a four-valve
semi-quantitative versus quantitative approach. J Heart Valve Dis
2013;22:491-9.
38. Fernandes AM, Rathi V, Biederman RW et al. Cardiovascular magnetic
resonance imaging-derived mitral valve geometry in determining mitral
regurgitation severity. Arq Bras Cardiol 2013;100:571-8.
39. Dyverfeldt P, Bissell M, Barker AJ et al. 4D flow cardiovascular
magnetic resonance consensus statement. J Cardiovasc Magn Reson
2015;17:72.
40. Roes SD, Hammer S, van der Geest RJ et al. Flow assessment through
four heart valves simultaneously using 3-dimensional 3-directional
velocity-encoded magnetic resonance imaging with retrospective valve
tracking in healthy volunteers and patients with valvular regurgitation.
Invest Radiol 2009;44:669-75.
41. Fidock B, Barker N, Balasubramanian N et al. A Systematic Review of
4D-Flow MRI Derived Mitral Regurgitation Quantification Methods. Front
Cardiovasc Med 2019;6:103.
42. Feneis JF, Kyubwa E, Atianzar K et al. 4D flow MRI quantification of
mitral and tricuspid regurgitation: Reproducibility and consistency
relative to conventional MRI. J Magn Reson Imaging 2018;48:1147-1158.
43. Van De Heyning CM, Magne J, Pierard LA et al. Late gadolinium
enhancement CMR in primary mitral regurgitation. Eur J Clin Invest
2014;44:840-7.
44. Kitkungvan D, Nabi F, Kim RJ et al. Myocardial Fibrosis in Patients
With Primary Mitral Regurgitation With and Without Prolapse. J Am Coll
Cardiol 2018;72:823-834.
45. Edwards NC, Moody WE, Yuan M et al. Quantification of left
ventricular interstitial fibrosis in asymptomatic chronic primary
degenerative mitral regurgitation. Circ Cardiovasc Imaging
2014;7:946-53.
46. Perazzolo Marra M, Basso C, De Lazzari M et al. Morphofunctional
Abnormalities of Mitral Annulus and Arrhythmic Mitral Valve Prolapse.
Circ Cardiovasc Imaging 2016;9:e005030.
47. Dejgaard LA, Skjolsvik ET, Lie OH et al. The Mitral Annulus
Disjunction Arrhythmic Syndrome. J Am Coll Cardiol 2018;72:1600-1609.
48. Flynn M, Curtin R, Nowicki ER et al. Regional wall motion
abnormalities and scarring in severe functional ischemic mitral
regurgitation: A pilot cardiovascular magnetic resonance imaging study.
J Thorac Cardiovasc Surg 2009;137:1063-70 e2.
49. Gillam LD, Schwartz A. Primum non nocere: the case for watchful
waiting in asymptomatic ”severe” degenerative mitral regurgitation.
Circulation 2010;121:813-21; discussion 821.
50. Tribouilloy C, Rusinaru D, Szymanski C et al. Predicting left
ventricular dysfunction after valve repair for mitral regurgitation due
to leaflet prolapse: additive value of left ventricular end-systolic
dimension to ejection fraction. Eur J Echocardiogr 2011;12:702-10.
51. Quintana E, Suri RM, Thalji NM et al. Left ventricular dysfunction
after mitral valve repair–the fallacy of ”normal” preoperative
myocardial function. J Thorac Cardiovasc Surg 2014;148:2752-60.
52. Enriquez-Sarano M, Suri RM, Clavel MA et al. Is there an outcome
penalty linked to guideline-based indications for valvular surgery?
Early and long-term analysis of patients with organic mitral
regurgitation. J Thorac Cardiovasc Surg 2015;150:50-8.
53. Suri RM, Schaff HV, Dearani JA et al. Determinants of early decline
in ejection fraction after surgical correction of mitral regurgitation.
J Thorac Cardiovasc Surg 2008;136:442-7.
54. Matsumura T, Ohtaki E, Tanaka K et al. Echocardiographic prediction
of left ventricular dysfunction after mitral valve repair for mitral
regurgitation as an indicator to decide the optimal timing of repair. J
Am Coll Cardiol 2003;42:458-63.
55. Uretsky S, Gillam LD. Myocardial fibrosis in asymptomatic
degenerative mitral regurgitation: what does T1 mapping tell us? Circ
Cardiovasc Imaging 2014;7:860-2.
56. Wong TC, Piehler KM, Kang IA et al. Myocardial extracellular volume
fraction quantified by cardiovascular magnetic resonance is increased in
diabetes and associated with mortality and incident heart failure
admission. Eur Heart J 2014;35:657-64.
57. Reddy ST, Belden W, Doyle M et al. Mitral regurgitation recovery and
atrial reverse remodeling following pulmonary vein isolation procedure
in patients with atrial fibrillation: a clinical observation
proof-of-concept cardiac MRI study. J Interv Card Electrophysiol
2013;37:307-15.
58. Chakravarty T, Van Belle E, Jilaihawi H et al. Meta-analysis of the
impact of mitral regurgitation on outcomes after transcatheter aortic
valve implantation. Am J Cardiol 2015;115:942-9.
59. Biederman RW, Magovern JA, Grant SB et al. LV reverse remodeling
imparted by aortic valve replacement for severe aortic stenosis; is it
durable? A cardiovascular MRI study sponsored by the American Heart
Association. J Cardiothorac Surg 2011;6:53.
60. Simprini LA, Afroz A, Cooper MA et al. Routine cine-CMR for
prosthesis-associated mitral regurgitation: a multicenter comparison to
echocardiography. J Heart Valve Dis 2014;23:575-82.
61. Krumm P, Zuern CS, Wurster TH et al. Cardiac magnetic resonance
imaging in patients undergoing percutaneous mitral valve repair with the
MitraClip system. Clin Res Cardiol 2014;103:397-404.
62. Hamilton-Craig C, Strugnell W, Gaikwad N et al. Quantitation of
mitral regurgitation after percutaneous MitraClip repair: comparison of
Doppler echocardiography and cardiac magnetic resonance imaging. Ann
Cardiothorac Surg 2015;4:341-51.
Figure Legends:
Figure 1: Steady state free precession sequence (SSFP) demonstrating 3
chamber view with central dephasing jet of MR between the A2-P2 scallops
of the mitral valve in one of our patients. MR: mitral regurgitation,
LA: left atrium, RV: right ventricle, LV: left ventricle, LVOT: left
ventricle outflow tract, AO: aorta
Figure 2: Steady state free precession sequence (SSFP) from our lab
demonstrating 3 chamber view with anteriorly directed dephasing jet of
MR with prolapse of the posterior mitral leaflet. MR: mitral
regurgitation, LA: left atrium, RV: right ventricle, LV: left ventricle,
LVOT: left ventricle outflow tract, AO: aorta
Figure 3a: Steady state free precession sequence (SSFP) from our lab
demonstrating 3 chamber view with flail posterior mitral valve leaflet
with eccentric jet of mitral regurgitation (white arrow). MR: mitral
regurgitation, LA: left atrium, RV: right ventricle, LV: left ventricle,
LVOT: left ventricle outflow tract, AO: aorta
Figure 3b: Steady state free precession sequence (SSFP) from our lab
demonstrating 4 chamber view with subtle flail posterior mitral valve
leaflet with eccentric jet of mitral regurgitation (white arrow). MR:
mitral regurgitation, LA: left atrium, RV: right ventricle, LV: left
ventricle, LVOT: left ventricle outflow tract, AO: aorta
Figure 4: Example CMR method for quantification of MR. The volume of the
LV is calculated during end-diastole (LVEDV) and during end-systole
(LVESV). The total volume of blood ejected from the left ventricle (LV),
LV SV, is computed as the difference between LV end-diastolic volume and
LV end-systolic volume. In this example LV SV is 150 mL. The volume of
blood crossing the aortic (AO) valve is measured by performance of a
phase-contrast acquisition in the aorta; in this example, 80 mL. The
mitral RVol (M RVol) is computed as the difference between the LV SV and
aortic forward SV; in this example, 70 mL.
Reused with permission from Zoghbi, William A., et al. ”Recommendations
for noninvasive evaluation of native valvular regurgitation: a report
from the American Society of Echocardiography developed in collaboration
with the Society for Cardiovascular Magnetic Resonance.” Journal of the
American Society of Echocardiography 30.4 (2017): 303-371.
Figure 5: Recommended cardiovascular magnetic resonance imaging
protocols for the assessment of mitral regurgitation. a Comprehensive
cardiovascular magnetic resonance imaging protocol for the assessment of
mitral regurgitation. b Focused, quantitative protocol. LGE, late
gadolinium enhancement; LV, left ventricular; LVOT, left ventricular
outflow tract; RVOT, right ventricular outflow tract. Reused under
Creative Commons Attribution 4.0 International Licence from Fig 1 in
Garg, Pankaj, et al. ”Assessment of mitral valve regurgitation by
cardiovascular magnetic resonance imaging.” Nature Reviews
Cardiology (2019): 1-15.
Figure 6: Depiction of mechanisms of MR as per the Carpentier
classification
Reused with permission from Zoghbi, William A., et al. ”Recommendations
for noninvasive evaluation of native valvular regurgitation: a report
from the American Society of Echocardiography developed in collaboration
with the Society for Cardiovascular Magnetic Resonance.” Journal of the
American Society of Echocardiography 30.4 (2017): 303-371.
Figure 7a: Steady state free precession sequence (SSFP) from our lab
demonstrating 3 chamber view in a patient with hypertrophic
cardiomyopathy with asymmetric septal hypertrophy and LVOT and SAM with
dense dephasing jet of MR
RV: Right ventricle, LV: Left ventricle, LA: Left atrium, Ao: Ascending
aorta, PM: Papillary muscle, LVOT: Left ventricular outflow tract
turbulence, SAM: Systolic anterior motion, MR: Mitral regurgitation
Figure 7b: Steady state free precession sequence (SSFP) demonstrating of
the same patient with hypertrophic cardiomyopathy showing two separate
jets of MR in a coronal view. LV: Left ventricle, RV: Right Ventricle,
AO: Ascending aorta, PA: Pulmonary artery, MR: Mitral Regurgitation
Figure 7c: Magnitude inversion recovery late gadolinium enhanced (LGE)
sequence demonstrating diffuse patchy hyperenhancement most prominent in
the inferolateral wall in the same patient with hypertrophic obstructive
cardiomyopathy and mitral regurgitation. RV: Right ventricule, IVS:
Interventricular septum, LV: Left Ventricle
Figure 8: Surgery-free survival stratified by both cardiovascular
magnetic resonance (CMR) regurgitant volume (RVol) and left ventricular
end-diastolic volume index (LVEDVi; Note that there were too few
subjects [n=2] with CMR regurgitant volume ≤55 mL and LVEDVi ≥100
mL/m2, so this group was excluded). B , CMR
regurgitant volume and echocardiographic mitral regurgitation (MR)
grade. Note that the group with CMR regurgitant volume >55
mL and moderate MR on echocardiography contains only 5 subjects.
Reused with permission from Myerson, Saul G., et al. ”Determination of
clinical outcome in mitral regurgitation with cardiovascular magnetic
resonance quantification.” Circulation 133.23 (2016): 2287-2296.